Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Johnson & Johnson Services, Inc.

organization80% conf.·synced Sep 25, 2026

Uses biomarkers to advance drug development and personalized treatment approaches across oncology, immunology, and neuroscience

60
sourced metrics
1255
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
278.43USD
Sep 10, 2026reference only
Market Cap
641876491311USD
Sep 10, 2026reference only
Price 52 Week Low
174.16USD
Sep 10, 2026reference only
Stock Return Ytd
28.5%
Sep 10, 2026reference only
Stock Price
266.35USD
Sep 10, 2026reference only
Shares Outstanding
2409898597.0shares
Jul 17, 2026reference only
Revenue
25310000000.0USD
Jun 28, 2026reference only
Stockholders Equity
84971000000.0USD
Jun 28, 2026reference only
Cost Of Revenue
8051000000.0USD
Jun 28, 2026reference only
Total Assets
201061000000.0USD
Jun 28, 2026reference only
Gross Profit
17259000000.0USD
Jun 28, 2026reference only
Total Liabilities
116090000000.0USD
Jun 28, 2026reference only
Cash
20422000000.0USD
Jun 28, 2026reference only
Eps
2.27USD_per_share
Jun 28, 2026reference only
Net Income
5534000000.0USD
Jun 28, 2026reference only
Operating Cash Flow
2514000000.0USD
Mar 29, 2026reference only
Capex
1049000000.0USD
Mar 29, 2026reference only
Rd Expense
109000000.0USD
Dec 28, 2025reference only

Stated objectives

Achieve full-year 2025 sales of $93.5B-$93.9B, representing growth of 5.4%-5.9%

source
target: 93.5-93.9 billion USD stated

Improve adjusted pretax operating margin by approximately 300 basis points driven by cost savings and reduced acquired IPR&D costs

source
target: ~300 bps improvement stated

Achieve 2026 top-line growth of more than 5%, exceeding consensus of ~4.6%

source
target: >5% revenue growth stated

Achieve 2026 adjusted EPS approximately $0.05 above consensus of $11.39, implying ~$11.44

source
target: ~$11.44 adjusted EPS stated

Submit OTTAVA robotic surgical system for regulatory approval in the United States

source
target: Regulatory submission completed stated

Achieve higher operational sales growth in both Innovative Medicine and MedTech segments in 2026

source
by 2026-01-01 00:00:00stated

Improve MedTech growth and margins by completing the pending separation of the Orthopaedics franchise

source
stated

Strengthen presence in the neurological and psychiatric drug market via acquisition of Intra-Cellular Therapies

source
stated

Develop and deploy Ottava next-generation robotic surgery platform with AI-enabled ecosystem

source
stated

J&J expects sales growth in both Innovative Medicine and MedTech segments to be higher in 2026

source
target: higher than 2025 growth rates by 2026-01-01 00:00:00stated

Relationship graph · 1255 connections

Developed by
511
Competes with
133
subsidiary of
81
Covered by
73
Employs
65
Owns
59
acquired by
52
regulates
36
board member of
Joaquin Duato
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com